Delivery of Antisense Oligonucleotides to the Cornea.
Fuchs' endothelial corneal dystrophy
cornea
corneal endothelium
oligonucleotide
Journal
Nucleic acid therapeutics
ISSN: 2159-3345
Titre abrégé: Nucleic Acid Ther
Pays: United States
ID NLM: 101562758
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
pubmed:
24
3
2020
medline:
20
8
2021
entrez:
24
3
2020
Statut:
ppublish
Résumé
Antisense oligonucleotides (ASOs) are synthetic nucleic acids that recognize complementary RNA sequences inside cells and modulate gene expression. In this study, we explore the feasibility of ASO delivery to the cornea. We used quantitative polymerase chain reaction to test the efficacy of a benchmark ASO targeting a noncoding nuclear RNA, Metastasis-Associated Lung Adenocarcinoma Transcript 1 (
Identifiants
pubmed: 32202944
doi: 10.1089/nat.2019.0838
pmc: PMC7415875
doi:
Substances chimiques
MALAT1 long non-coding RNA, human
0
Oligonucleotides, Antisense
0
RNA, Long Noncoding
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
207-214Subventions
Organisme : NEI NIH HHS
ID : P30 EY030413
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY027785
Pays : United States
Organisme : NIGMS NIH HHS
ID : R35 GM118103
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY022161
Pays : United States
Références
JAMA Ophthalmol. 2016 Jul 1;134(7):810-6
pubmed: 27136069
Annu Rev Vis Sci. 2019 Sep 15;5:151-175
pubmed: 31525145
World J Pharmacol. 2013;2(2):47-64
pubmed: 25590022
J Pharmacol Exp Ther. 2009 May;329(2):496-504
pubmed: 19208899
Am J Ophthalmol. 2002 Apr;133(4):552-6
pubmed: 11931791
Surv Ophthalmol. 2018 Mar - Apr;63(2):193-213
pubmed: 29080632
Prog Retin Eye Res. 2008 Mar;27(2):177-96
pubmed: 18243038
Invest Ophthalmol Vis Sci. 1990 Oct;31(10):1957-62
pubmed: 2210991
Surv Ophthalmol. 2017 Nov - Dec;62(6):770-783
pubmed: 28688894
Nat Neurosci. 2017 Apr;20(4):497-499
pubmed: 28192393
Biochim Biophys Acta. 2016 Oct;1858(10):2421-2430
pubmed: 26898663
Nucleic Acid Ther. 2019 Apr;29(2):73-81
pubmed: 30676271
Invest Ophthalmol Vis Sci. 2012 Mar 09;53(3):1195-203
pubmed: 22323484
N Engl J Med. 2015 Mar 26;372(13):1193-203
pubmed: 25692915
Prog Retin Eye Res. 2017 Mar;57:134-185
pubmed: 28028001
Cornea. 2014 Jan;33(1):96-8
pubmed: 24270677
Am J Hum Genet. 2018 Apr 5;102(4):528-539
pubmed: 29526280
J Child Neurol. 2016 Jun;31(7):899-906
pubmed: 26823478
JAMA Ophthalmol. 2016 Feb;134(2):167-73
pubmed: 26633035
N Engl J Med. 2017 Nov 2;377(18):1723-1732
pubmed: 29091570
Invest Ophthalmol Vis Sci. 2017 Dec 1;58(14):6308-6317
pubmed: 29242905
Invest Ophthalmol Vis Sci. 2008 Jan;49(1):93-104
pubmed: 18172080
Hum Mol Genet. 2018 Mar 15;27(6):1015-1026
pubmed: 29325021
Nucleic Acids Res. 2018 Feb 28;46(4):1584-1600
pubmed: 29240946
Annu Rev Pharmacol Toxicol. 2017 Jan 6;57:81-105
pubmed: 27732800
Drug Deliv Transl Res. 2016 Dec;6(6):735-754
pubmed: 27798766
PLoS One. 2012;7(11):e49083
pubmed: 23185296
Asia Pac J Ophthalmol (Phila). 2016 Jul-Aug;5(4):272-81
pubmed: 27213768
Invest Ophthalmol Vis Sci. 2014 Nov 06;55(12):7821-30
pubmed: 25377225
Ophthalmology. 2014 Sep;121(9):1683-92
pubmed: 24811963
Invest Ophthalmol Vis Sci. 2015 Feb 26;56(3):2003-11
pubmed: 25722209
Nucleic Acid Ther. 2019 Jun;29(3):116-122
pubmed: 30907681
Invest Ophthalmol Vis Sci. 2017 Sep 1;58(11):4579-4585
pubmed: 28886202
Lancet. 2012 May 5;379(9827):1749-61
pubmed: 22559901
Invest Ophthalmol Vis Sci. 2001 Oct;42(11):2646-51
pubmed: 11581212
Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4072-8
pubmed: 16249482
Sci Transl Med. 2018 Oct 31;10(465):
pubmed: 30381411